DPx Launched as Provider of Pharmaceutical Services, Fine Chemicals, and Proprietary Technologies
$2.6 billion transaction combines Patheon and DSM Pharmaceutical to create CDMO, DPx.
DPx Holdings is a new CDMO for the pharmaceutical and related industries, formed from a $2.65 billion transaction between JLL Partners, a private equity firm, and Royal DSM, a life-sciences and materials sciences company. DPx is 51% owned by JLL Partners and 49% by Royal DSM.
Formerly known by its provisional name “NewCo,” DPx is the corporate parent of a group of business units that is comprised of three brands focused on pharmaceutical services, fine chemicals and products, and proprietary technologies. These units are the result of combining DSM Pharmaceutical Products (DPP), Patheon, and Banner Life Sciences.
Pharmaceutical services will operate under the Patheon brand name and include the CMO capabilities, pharmaceutical product development services, as well as biosolutions and biologics businesses of DPP. In addition, fine chemicals, or the ES/IM and API businesses, will operate under the brand name DSM Fine Chemicals, while proprietary products and technologies will operate under Banner Life Sciences.
DSM Fine Chemicals will also handle complicated APIs and finished dosage forms, and Banner Life Sciences will offer its own proprietary and nutraceutical products to the market.
DPx’s 2014 sales are expected to be about $2 billion (pro-forma). DPx has 24 locations across North America, Europe, Latin America, and Australia with more than 8000 employees.
Source: DPx Holdings
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
